Intermittent intravenous ibandronate therapy for osteoporosis

Abstract

The author consecutively considers the introduction of intermittent use of ibandronate (I), by determining its single dose and annual cumulative dose. She presents data on the adequate antiresorptive activity of intermittent treatment, shows it necessary to design an intravenous dosage form of the drug and gives detailed data on the efficacy of parenteral I. The fact that the agent may be used in secondary (steroidal) osteoporosis is provided. There is evidence that the risk of extravertebral and all clinical fractures reduces when I is intravenously injected in a dose of 3 mg quarterly and orally administered in a dose of 150 mg monthly.